Cargando…

Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1

The Omicron BA.1 variant emerged in late 2021 and quickly spread across the world. Compared to the earlier SARS-CoV-2 variants, BA.1 has many mutations, some of which are known to enable antibody escape. Many of these antibody-escape mutations individually decrease the spike receptor-binding domain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moulana, Alief, Dupic, Thomas, Phillips, Angela M., Chang, Jeffrey, Nieves, Serafina, Roffler, Anne A., Greaney, Allison J., Starr, Tyler N., Bloom, Jesse D., Desai, Michael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668218/ https://www.ncbi.nlm.nih.gov/pubmed/36384919 http://dx.doi.org/10.1038/s41467-022-34506-z

Ejemplares similares

The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
por: Moulana, Alief, et al.
Publicado: (2023)

Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains
por: Starr, Tyler N., et al.
Publicado: (2022)

Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies
por: Phillips, Angela M, et al.
Publicado: (2021)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
por: Huo, Jiandong, et al.
Publicado: (2023)

Modular epistasis and the compensatory evolution of gene deletion mutants
por: Rojas Echenique, José I., et al.
Publicado: (2019)

Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1
por: Li, Linjie, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2
por: Golcuk, Mert, et al.
Publicado: (2022)

Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

ACE2 binding is an ancestral and evolvable trait of sarbecoviruses
por: Starr, Tyler N., et al.
Publicado: (2022)

Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages: Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes
por: Verkhivker, Gennady, et al.
Publicado: (2023)

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination
por: Bellusci, Lorenza, et al.
Publicado: (2022)

Compensatory mutations cause excess of antagonistic epistasis in RNA secondary structure folding
por: Wilke, Claus O, et al.
Publicado: (2003)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
por: Zhang, Lianghui, et al.
Publicado: (2022)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice
por: Rizvi, Zaigham Abbas, et al.
Publicado: (2023)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant
por: Zhang, Haoran, et al.
Publicado: (2022)

Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2
por: Philip, Angelin M., et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Selection Is a Significant Driver of Gene Gain and Loss in the Pangenome of the Bacterial Genus Sulfurovum in Geographically Distinct Deep-Sea Hydrothermal Vents
por: Moulana, Alief, et al.
Publicado: (2020)

Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability
por: Julian, Mark C., et al.
Publicado: (2017)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Binding affinity improvement analysis of multiple-mutant Omicron on 2019-nCov to human ACE2 by in silico predictions
por: Li, Bo, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses
por: Sims, Joshua J., et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

Two human monoclonal SARS-CoV-2 antibodies that maintain neutralizing potency against the SARS-CoV-2 Omicron BA.1 and BA.2 variants
por: Zheng, Qianqian, et al.
Publicado: (2022)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Evolutionary pathways to SARS-CoV-2 resistance are opened and closed by epistasis acting on ACE2
por: Castiglione, Gianni M., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p7dr97m7lrutp0209la75u623s